Quantcast

DaVita Clinical Research Presents Research Results at the American Nephrology Nurses Association National Symposium

April 14, 2014

ANAHEIM, Calif., April 14, 2014 /PRNewswire-USNewswire/ — DaVita Clinical Research (DCR) (NYSE: DVA), a specialty contract research organization with services spanning the full spectrum of drug and device development, today announced that company representatives will present four abstracts at the American Nephrology Nurses Association (ANNA) 45(th) National Symposium scheduled for April 13-16, 2014 in Anaheim, Calif.

http://photos.prnewswire.com/prnvar/20140212/DC63568LOGO

ANNA is designed to provide an educational and networking environment for nephrology nurses and practice administrators to expand knowledge, enhance clinical skills, and translate evidence into daily practice.

“At DaVita, we’re committed to improving the care of patients with renal disease by focusing on translational research,” said Mahesh Krishnan, M.D., M.P.H., M.B.A., F.A.S.N., vice president clinical innovation and public policy at DaVita. “Presenting our research initiatives here at ANNA creates an ideal platform to translate those findings into clinical care for kidney patients.”

Researchers from DaVita, the dialysis division of DaVita Healthcare Partners Inc., and DCR will present results from a number of innovative clinical improvement programs originating from DaVita and its research partners. DCR seeks to advance the future of medicine, the practice of medicine and to innovate through personalized medicine. DCR and DaVita share a dedication to improving the health and quality of life for kidney care patients.

DaVita will focus on meaningful research initiatives in end-stage renal disease, including:

    --  "Choice of Drain Systems and Associated Peritonitis Rates in Automated
        Peritoneal Dialysis Patients," oral presentation by Michelle Cassin,
        R.N., C.P.D.N. on Monday, April 14 in Abstract Concurrent Session #162,
        from 5:35 p.m.-5:55 p.m.
    --  "Hemodialysis Session Length Has a Dose Relationship With Hazard Rates
        of Cause-Specific Hospitalization and Mortality," oral presentation by
        Irina Goykhman, R.N., B.S.N., M.B.A. on Monday, April 14 in Abstract
        Concurrent Session #161, from 4:20 p.m.- 4:40 p.m.
    --  "A Pilot Quality Improvement Program to Minimize Catheter-Related
        Bloodstream Infection in an Outpatient Hemodialysis Setting," poster
        presentation by Nancy Culkin, B.S.N., R.N., C.N.N.
    --  "A Standardized Algorithm for Peritonitis Surveillance," poster
        presentation by Michelle Cassin, R.N., C.P.D.N.

Poster presentations will be held Monday, April 14, 2:45 p.m.-4:15 p.m. and Tuesday, April 15, 9:00 a.m.-10:15 a.m.

DaVita, DaVita Clinical Research, and DCR are trademarks or registered trademarks of DaVita Healthcare Partners Inc.

About DaVita

DaVita is the dialysis division of DaVita HealthCare Partners Inc., a Fortune 500® company that, through its operating divisions, provides a variety of health care services to patient populations throughout the United States and abroad. A leading provider of kidney care in the United States, DaVita delivers dialysis services to patients with chronic kidney failure and end stage renal disease. DaVita strives to improve patients’ quality of life by innovating clinical care, and by offering integrated treatment plans, personalized care teams and convenient health-management services. As of Dec. 31, 2013, DaVita operated or provided administrative services at 2,074 outpatient dialysis centers located in the United States serving approximately 163,000 patients. The company also operated 73 outpatient dialysis centers located in ten countries outside the United States. DaVita supports numerous programs dedicated to creating positive, sustainable change in communities around the world. The company’s leadership development initiatives and social responsibility efforts have been recognized by Fortune, Modern Healthcare, Newsweek and WorldBlu. For more information, please visit DaVita.com.

About DaVita Clinical Research

DaVita Clinical Research (DCR), a wholly owned subsidiary of DaVita HealthCare Partners Inc. (NYSE: DVA), uses its extensive, applied database and real-world healthcare experience to assist pharmaceutical and medical device companies in the design, recruitment and completion of retrospective, prospective pragmatic and clinical trials. DCR’s scientific and clinical expertise spans the lifecycle of product development with more than 150 client companies. DCR’s Biorepository, Early Clinical Research unit (Phase I-IIa) and Clinical Development (Phase IIb through post-marketing) network of physicians and investigative sites, data research, Health Economics & Outcomes Research, and Medical Communications are focused on providing world-class research in both complex/specialty populations and therapeutic areas, and especially in CKD and ESRD populations. To learn more about DCR, visit www.davitaclinicalresearch.com.

Logo – http://photos.prnewswire.com/prnh/20140212/DC63568LOGO

Contact Information

Media:


Bianca Violante

Office: (303) 876-661

Mobile: (443) 417-6044

Bianca.Violante@DaVita.com

SOURCE DaVita Clinical Research


Source: PR Newswire



comments powered by Disqus